Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and GVHD

功能不同的树突状细胞亚群在耐受性和 GVHD 中的作用

基本信息

  • 批准号:
    8375902
  • 负责人:
  • 金额:
    $ 27.99万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-07-01 至
  • 项目状态:
    未结题

项目摘要

Project 4. Role of Functionally Distinct Dendritic Cell Subsets in Tolerance and Graft-Versus-Host Disease We recently discovered that effector T cell subsets, including THI, TH2 and Treg cells, can induce monocytes to differentiate into dendritic cells (DCs) that, in turn, selectively induce the formation of THI, TH2 and Treg cells from naive T cells, respectively. We hypothesize that this heretofore unknown immunoregulatory mechanism may play an important role in the control of protective immunity, including proinflammatory responses and tolerance induction, as well as pathologic immunity such as that seen in graft versus host disease (GVHD). We further believe that it may be possible to target and /or manipulate these novel DC subsets to treat or prevent such disorders. The overall goals of this project are to assess the possible role of immunoregulatory DCs (DCrreg) in immune tolerance and GVHD in recipients of hematopoetic stem cell transplants with or without organ transplants, and identify molecules that induce the formation and mediate the functions of these DCs. These goals will be pursued by 1) assessing and comparing the phenotypic, functional and gene expression profiles of T cells and non-T antigen presenting cells in the blood and kidneys of transplant recipients who are immunologically tolerant of their grafts versus those who are not, 2) using neutralizing antibodies and gene expression profiling to identify key factors expressed by Treg cells that are responsible for inducing monocytes to differentiate into DCxreg, as well as the key factors expressed by DCrreg that are responsible for inducing the formation of Treg cells from naive T cells, and 3) evaluating the effects of DCrreg, as well as Treg cells induced by DCrreg, in a murine model of acute GVHD and organ transplant tolerance. This Project is highly dependent on interactions with Projects 1 and 3 as well as Cores B and C, which are the sources of clinical materials, mouse models and immune and gene profiling assays, respectively. Success in this project should ultimately lead to safer and more effective ways to achieve immune tolerance in the setting of allogeneic transplantation.
项目4。功能不同的树突状细胞亚群在免疫耐受和移植物抗宿主中的作用 我们最近发现,效应T细胞亚群,包括TH 1、TH 2和Treg细胞,可以诱导单核细胞分化成树突细胞(DC),树突细胞(DC)进而分别选择性地诱导来自初始T细胞的TH 1、TH 2和Treg细胞的形成。我们推测,这种迄今未知的免疫调节机制可能在保护性免疫的控制中发挥重要作用,包括促炎反应和耐受诱导,以及病理性免疫,如移植物抗宿主病(GVHD)。我们进一步相信,有可能靶向和/或操纵这些新的DC亚群来治疗或预防此类疾病。本课题的总体目标是探讨免疫调节性DCs(DCrreg)在造血干细胞移植受者免疫耐受和GVHD中的作用 有或没有器官移植的移植,并鉴定诱导这些DC形成和介导这些DC功能的分子。这些目标将通过以下方式实现:1)评估和比较T细胞和非T抗原呈递细胞在移植受体的血液和肾脏中的表型、功能和基因表达谱,所述移植受体对其移植物具有免疫耐受性,而所述移植受体对其移植物不具有免疫耐受性,(二)使用中和抗体和基因表达谱来鉴定由Treg细胞表达的负责诱导单核细胞分化成DCxreg的关键因子,以及由DCrreg表达的负责诱导由初始T细胞形成Treg细胞的关键因子,和3)评估DCrreg以及由DCrreg诱导的Treg细胞在急性GVHD和器官移植耐受性的鼠模型中的作用。本项目高度依赖于与项目1和3以及核心B和C的相互作用,这些核心是临床材料、小鼠模型以及免疫和基因分析测定的来源, 分别该项目的成功最终将导致在同种异体移植中实现免疫耐受的更安全和更有效的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

EDGAR G. ENGLEMAN其他文献

EDGAR G. ENGLEMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('EDGAR G. ENGLEMAN', 18)}}的其他基金

Project 1 Mouse Models Analysis
项目1 小鼠模型分析
  • 批准号:
    10729466
  • 财政年份:
    2023
  • 资助金额:
    $ 27.99万
  • 项目类别:
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic Progression
转移进展中肿瘤-免疫-基质相互作用的系统生物学
  • 批准号:
    10729464
  • 财政年份:
    2023
  • 资助金额:
    $ 27.99万
  • 项目类别:
Targeting Lymph Node Dependent Immune Tolerance in Cancer
针对癌症中的淋巴结依赖性免疫耐受
  • 批准号:
    10210557
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
项目 3:肿瘤遗传学对 PDAC 免疫生物学的影响以及对巨噬细胞靶向免疫治疗的反应
  • 批准号:
    10704089
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
肥胖导致癌症生长的先天免疫机制
  • 批准号:
    10654802
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
肥胖导致癌症生长的先天免疫机制
  • 批准号:
    10430268
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
肥胖导致癌症生长的先天免疫机制
  • 批准号:
    10278250
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
项目 3:肿瘤遗传学对 PDAC 免疫生物学的影响以及巨噬细胞靶向免疫治疗的反应
  • 批准号:
    10456771
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
肥胖导致癌症生长的先天免疫机制
  • 批准号:
    10706825
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:
Targeting Lymph Node Dependent Immune Tolerance in Cancer
针对癌症中的淋巴结依赖性免疫耐受
  • 批准号:
    10366092
  • 财政年份:
    2021
  • 资助金额:
    $ 27.99万
  • 项目类别:

相似海外基金

Operational tolerance induction by alloantigen-induced Treg cell therapy in rat lung transplantation
同种异体抗原诱导的 Treg 细胞疗法在大鼠肺移植中诱导操作耐受
  • 批准号:
    23K08289
  • 财政年份:
    2023
  • 资助金额:
    $ 27.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10432434
  • 财政年份:
    2022
  • 资助金额:
    $ 27.99万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10744193
  • 财政年份:
    2022
  • 资助金额:
    $ 27.99万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10534556
  • 财政年份:
    2022
  • 资助金额:
    $ 27.99万
  • 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10612453
  • 财政年份:
    2022
  • 资助金额:
    $ 27.99万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10204102
  • 财政年份:
    2019
  • 资助金额:
    $ 27.99万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10443701
  • 财政年份:
    2019
  • 资助金额:
    $ 27.99万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10737340
  • 财政年份:
    2019
  • 资助金额:
    $ 27.99万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10652374
  • 财政年份:
    2019
  • 资助金额:
    $ 27.99万
  • 项目类别:
Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use
生成用于诊断和研究用途的同种异体抗原特异性设计血小板
  • 批准号:
    9005358
  • 财政年份:
    2016
  • 资助金额:
    $ 27.99万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了